Keen Vision Acquisition Corporation KVAC 深 沪
已收盘 08-01 16:00:00 美东时间
11.48
-0.020
-0.17%
华盛通- 最 高11.535
- 今 开11.535
- 成交量 6.96万股
- 最 低 11.48
- 昨 收 11.50
- 总市值 1.24亿
- 52周最高 11.59
- 市盈率 静 27.76
- 换手率 0.00%
- 52周最低 10.66
- 委 比 41.18%
- 总股本 1082.07万
- 历史最高 11.59
- 量 比 2.38
- 振 幅 0.48%
- 历史最低 10.14
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Keen Vision Extends Business Combination Period
Keen Vision Acquisition Corporation ( ($KVAC) ) has shared an announcement. On ...
07-25 04:42
Medera And University Of Kansas Medical Center Announce Treatment Of First Patient In MUSIC-DMD Phase 1b Clinical Trial For Duchenne Muscular Dystrophy
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, and its clinical development division Sardocor, together with
07-15 20:11
Keen Vision Issues Promissory Note to Extend Deadline
The latest announcement is out from Keen Vision Acquisition Corporation ( ($KVA...
06-28 04:47
Medera And Novoheart Collaborate With Physician-Scientists At University Of California San Diego School Of Medicine And Mayo Clinic To Develop Mini-Heart Models Aimed At Transforming Treatment For HLHS
First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatmentsPartnership aims to improve survival and quality
06-24 20:10
Keen Vision Extends Business Combination Period
Keen Vision Acquisition Corporation ( ($KVAC) ) has shared an update. On May 20...
05-24 05:46
Medera Showcases Interim Data From First-in-Human Gene Therapy Trial For HFpEF In Late-Breaking Presentation At Heart Failure 2025 Congress; Clinical Trial Show Favorable Safety Profile And Early Clinical Benefits With SRD-002 Gene Therapy
Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapyBOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage
05-19 20:06
在“市场艺术”中重构De-SPAC估值锚点
登录新浪财经APP 搜索【信披】查看更多考评等级 作者:“亚洲SPAC教父”、诺圻资本主席王干文 众所周知,传统IPO的发行定价通常是...
03-25 15:08
单月IPO规模超10亿美元，医药企业上市全面转暖
转自：新康界 2024年9月，在生物医药领域，有7家公司采取IPO形式上市，5家公司SPAC合并上市。 一、IPO上市 9月是生物医药公司IPO的传统旺季，共有...
2024-10-28 17:51
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KVAC, CNOB, FLIC on Behalf of Shareholders
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2024-09-06 04:39
Medera To Be Listed On NASDAQ Through A Merger Agreement With Keen Vision Acquisition Corporation
Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human
2024-09-05 20:17
